Oral application of T4 phage induces weak antibody production in the gut and in the blood

Viruses

Volumn 7, Issue 8, 2015, Pages 4783-4799

  Majewska, Joanna ^a   Beta, Weronika ^a   Lecion, Dorota ^a   Hodyra Stefaniak, Katarzyna ^a   Kłopot, Anna ^a   Kazmiercźak, Zuzanna ^a   Miernikiewicz, Paulina ^a   Piotrowicz, Agnieszka ^a   Ciekot, Jarosław ^a   Owczarek, Barbara ^a   Kopciuch, Agnieszka ^a   Wojtyna, Karolina ^a   Harhala, Marek ^a   Mąkosa, Mateusz ^a   Dąbrowska, Krystyna ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antibodies; Capsid proteins; Ebola virus; EBOV; Oral administration; Phage display; Phage resistance; T4 phage; Vaccine

Indexed keywords

CAPSID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SECRETORY IMMUNOGLOBULIN; STRUCTURAL PROTEIN; GP12 PROTEIN, ENTEROBACTERIA PHAGE T4; HOC PROTEIN, T4 PHAGE; IMMUNOGLOBULIN A; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

AFFINITY CHROMATOGRAPHY; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIUM COLONY; CONTROLLED STUDY; DNA SEQUENCE; EBOLAVIRUS; ENTEROBACTERIA PHAGE T4; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; VIROLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACTERIOPHAGE T4; BLOOD; CAPSID PROTEINS; EBOLAVIRUS; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LONGITUDINAL STUDIES; MALE; MICE, INBRED C57BL; VIRAL STRUCTURAL PROTEINS;

EID: 84941143176     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7082845     Document Type: Article

References (47)

1. Abedon, S.T.; Kuhl, S.J.; Blasdel, B.G.; Kutter, E.M. Phage treatment of human infections. Bacteriophage 2011, 1, 66-85. [CrossRef] [PubMed]
2. Bruttin, A.; Brüssow, H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 2005, 49, 2874-2878. [CrossRef] [PubMed]
3. Kutter, E.; de Vos, D.; Gvasalia, G.; Alavidze, Z.; Gogokhia, L.; Kuhl, S.; Abedon, S.T. Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol. 2010, 11, 69-86. [CrossRef] [PubMed]
4. Międzybrodzki, R.; Borysowski, J.; Weber-Dąbrowska, B.; Fortuna, W.; Letkiewicz, S.; Szufnarowski, K.; Pawełczyk, Z.; Rogóż, P.; Kłak, M.; Wojtasik, E.; et al. Clinical aspects of phage therapy. Adv. Virus Res. 2012, 83, 73-121. [PubMed]
5. Sarker, S.A.; McCallin, S.; Barretto, C.; Berger, B.; Pittet, A.C.; Sultana, S.; Krause, L.; Huq, S.; Bibiloni, R.; Bruttin, A.; et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012, 434, 222-232. [CrossRef] [PubMed]
6. Wolska, K.; Kot, B.; Piechota, M.; Frankowska, A. Resistance of Pseudomonas aeruginosa to antibiotics. Postep. Hig. Med. Dosw. 2013, 67, 1300-1311. [CrossRef]
7. Przybylski, M.; Borysowski, J.; Jakubowska-Zahorska, R.; Weber-Dąbrowska, B.; Górski, A. T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro. Future Microbiol. 2015, 10, 453-460. [CrossRef] [PubMed]
8. Jiang, J.; Abu-Shilbayeh, L.; Rao, V.B. Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect. Immun. 1997, 65, 4770-4777. [PubMed]
9. Shivachandra, S.B.; Rao, M.; Janosi, L.; Sathaliyawala, T.; Matyas, G.R.; Alving, C.R.; Leppla, S.H.; Rao, V.B. In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: A strategy for efficient display of large full-length proteins. Virology 2006, 345, 190-198. [CrossRef] [PubMed]
10. Shivachandra, S.B.; Li, Q.; Peachman, K.K.; Matyas, G.R.; Leppa, S.H.; Alving, C.R.; Rao, M.; Rao, V.B. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 2007, 25, 1225-1235. [CrossRef] [PubMed]
11. Ren, Z.J.; Lewis, G.K.; Wingfield, P.T.; Locke, E.G.; Steven, A.C.; Black, L.W. Phage display of intact domains at high copy number: A system based on Soc, the small outer capsid protein of bacteriophage T4. Protein Sci. 1996, 5, 1833-1843. [CrossRef] [PubMed]
12. Sathaliyawala, T.; Rao, M.; Maclean, D.M.; Birx, D.L.; Alving, C.R.; Rao, V.B. Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: A novel in vitro approach to construct multicomponent HIV vaccines. J. Virol. 2006, 80, 7688-7698. [CrossRef] [PubMed]
13. Kamme, C. Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 1973, 81, 741-748. [PubMed]
14. Smith, H.W.; Huggins, M.B.; Shaw, K.M. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J. Gen. Microbiol. 1987, 133, 1127-1135. [CrossRef] [PubMed]
15. Górski, A.; Międzybrodzki, R.; Borysowski, J.; Dąbrowska, K.; Wierzbicki, P.; Ohams, M.; Korczak-Kowalska, G.; Olszowska-Zaremba, N.; Łusiak-Szelachowska, M.; Kłak, M.; et al. Phage as a modulator of immune responses: Practical implications for phage therapy. Adv. Virus Res. 2012, 83, 41-71. [PubMed]
16. Górski, A.; Wazna, E.; Dabrowska, B.W.; Dabrowska, K.; Switała-Jelén, K.; Miedzybrodzki, R. Bacteriophage translocation. FEMS Immunol Med. Microbiol. 2006, 46, 313-319. [CrossRef] [PubMed]
17. Łusiak-Szelachowska, M.; Zaczek, M.; Weber-Dąbrowska, B.; Międzybrodzki, R.; Kłak, M.; Fortuna, W.; Letkiewicz, S.; Rogóż, P.; Szufnarowski, K.; Jónczyk-Matysiak, E.; et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 2014, 27, 295-304. [CrossRef] [PubMed]
18. Dąbrowska, K.; Miernikiewicz, P.; Piotrowicz, A.; Hodyra, K.; Owczarek, B.; Lecion, D.; Kázmierczak, Z.; Letarov, A.; Górski, A. Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 2014, 88, 12551-12557. [CrossRef] [PubMed]
19. Huff, W.E.; Huff, G.R.; Rath, N.C.; Donoghue, A.M. Immune interference of bacteriophage efficacy when treating colibacillosis in poultry. Poult. Sci. 2010, 89, 895-900. [CrossRef] [PubMed]
20. Reyes, A.; Semenkovich, N.P.; Whiteson, K.; Rohwer, F.; Gordon, J.I. Going viral: Next-generation sequencing applied to phage populations in the human gut. Nat. Rev. Microbiol. 2012, 10, 607-617. [CrossRef] [PubMed]
21. Reyes, A.; Wu, M.; McNulty, N.P.; Rohwer, F.L.; Gordon, J.I. Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc. Natl. Acad. Sci. USA 2013, 110, 20236-20241. [CrossRef] [PubMed]
22. Dalmasso, M.; Hill, C.; Ross, R.P. Exploiting gut bacteriophages for human health. Trends Microbiol. 2014, 22, 399-405. [CrossRef] [PubMed]
23. Duerkop, B.A.; Hooper, L.V. Resident viruses and their interactions with the immune system. Nat. Immunol. 2013, 14, 654-659. [CrossRef] [PubMed]
24. Dabrowska, K.; Switała-Jelen, K.; Opolski, A.; Weber-Dabrowska, B.; Gorski, A. Bacteriophage penetration in vertebrates. J. Appl. Microbiol. 2005, 98, 7-13. [CrossRef] [PubMed]
25. Miura, K.; Orcutt, A.C.; Muratova, O.V.; Miller, L.H.; Saul, A.; Long, C.A. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 2008, 26, 193-200. [CrossRef] [PubMed]
26. Miura, K.; Takashima, E.; Deng, B.; Tullo, G.; Diouf, A.; Moretz, S.E.; Nikolaeva, D.; Diakite, M.; Fairhurst, R.M.; Fay, M.P.; et al. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Infect. Immun. 2013, 81, 4377-4382. [CrossRef] [PubMed]
27. Ceglarek, I.; Piotrowicz, A.; Lecion, D.; Miernikiewicz, P.; Owczarek, B.; Hodyra, K.; Harhala, M.; Górski, A.; Dąbrowska, K. A novel approach for separating bacteriophages from other bacteriophages using affinity chromatography and phage display. Sci. Rep. 2013, 3, 3220. [CrossRef] [PubMed]
28. Weber-Dabrowska, B.; Dabrowski, M.; Slopek, S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. 1987, 35, 563-568.
29. Keller, R.; Engley, F.B. Fate of bacteriophage particles introduced into mice by various routes. Proc. Soc. Exp. Biol. Med. 1958, 98, 577-579. [CrossRef] [PubMed]
30. Hoffmann, M. Animal experiments on the mucosal passage and absorption viremia of T3 phages after oral, tracheal and rectal administration. Zentralbl. Bacteriol. Orig. 1965, 198, 371-390.
31. Fogelman, I.; Davey, V.; Ochs, H.D.; Elashoff, M.; Feinberg, M.B.; Mican, J.; Siegel, J.P.; Sneller, M.; Lane, H.C. Evaluation of CD4 T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J. Infect. Dis. 2000, 182, 435-441. [CrossRef] [PubMed]
32. Merril, C.R.; Biswas, B.; Carlton, R.M.; Jensen, N.C.; Creed, G.J.; Zullo, S.; Adhya, S. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 1996, 93, 3188-3192. [CrossRef] [PubMed]
33. Geier, M.R.; Trigg, M.E.; Merril, C.R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973, 246, 221-223. [CrossRef] [PubMed]
34. Borysowski, J.; Górski, A. Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 2008, 12, 466-471. [CrossRef] [PubMed]
35. Mordenti, J.; Chen, S.A.; Moore, J.A.; Ferraiolo, B.L.; Green, J.D. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991, 8, 1351-1359. [CrossRef] [PubMed]
36. Sulakvelidze, A.; Alavidze, Z.; Morris, J.G., Jr. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45, 649-659. [CrossRef] [PubMed]
37. Maura, D.; Debarbieux, L. On the interactions between virulent bacteriophages and bacteria in the gut. Bacteriophage 2012, 2, 229-233. [CrossRef] [PubMed]
38. Weiss, M.; Denou, E.; Bruttin, A.; Serra-Moreno, R.; Dillmann, M.L.; Brüssow, H. In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology 2009, 393, 16-23. [CrossRef] [PubMed]
39. Clark, J.R.; March, J.B. Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol. 2006, 24, 212-218. [CrossRef] [PubMed]
40. Clark, J.R.; March, J.B. Bacteriophage mediated nucleic acid immunisation. FEMS Immunol. Med. Microbiol. 2004, 40, 21-26. [CrossRef]
41. Xu, L.; Sanchez, A.; Yang, Z.; Zaki, S.R.; Nabel, E.G.; Nichol, S.T.; Nabel, G.J. Immunization for Ebola virus infection. Nat. Med. 1998, 4, 37-42. [CrossRef] [PubMed]
42. Shedlock, D.J.; Aviles, J.; Talbott, K.T.; Wong, G.; Wu, S.J.; Villarreal, D.O.; Myles, D.J.; Croyle, M.A.; Yan, J.; Kobinger, G.P.; et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol. Ther. 2013, 21, 1432-1444. [CrossRef] [PubMed]
43. Becquart, P.; Mahlakõiv, T.; Nkoghe, D.; Leroy, E.M. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS ONE 2014, 9, e96360. [CrossRef] [PubMed]
44. Miernikiewicz, P.; Owczarek, B.; Piotrowicz, A.; Boczkowska, B.; Rzewucka, K.; Figura, G.; Letarov, A.; Kulikov, E.; Kopciuch, A.; Świtała-Jelén, K.; et al. Recombinant expression and purification of T4 phage Hoc, Soc, gp23, gp24 proteins in native conformations with stability studies. PLoS ONE 2012, 7, e38902. [CrossRef] [PubMed]
45. Miernikiewicz, P.; Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland. Personal Communication, 2013.
46. Kilkenny, C.; Browne, W.J.; Cuthill, I.C.; Emerson, M.; Altman, D.G. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 2010, 8, e1000412. [CrossRef] [PubMed]
47. StatSoft, Inc. STATISTICA (data analysis software system), version 8.0. Available online: http://www.statsoft.com (accessed on 20 April 2015).